Hailshadow
- Sarepta Therapeutics (SRPT) is up ~10% in after-hours trading Friday after announcing it will release topline, 3-year results from its EMBARK study of Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy the morning of Jan. 26.
- The data from part 1
